search
Back to results

Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris

Primary Purpose

Acne Vulgaris

Status
Not yet recruiting
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Isotretinoin ,silymarin
Sponsored by
Tanta University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne Vulgaris

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age: 16 years or more. Patient with moderate or severe acne. Not receiving acne treatment in the last month. Exclusion Criteria: Pregnancy or lactation. Patients with known hypersensitivity to isotretinoin or silymarin. Patients with depression, liver diseases or high cholesterol. Patients with acromegaly. Patients with chronic inflammatory, infective or neoplastic disorders.

Sites / Locations

  • Tanta University

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

acne vulgaris patients group 1

acne vulgaris patients group 2

acne vulgaris patients group 3

Arm Description

acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)

acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)

acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)

Outcomes

Primary Outcome Measures

Global Acne Grading Classification
Global Acne Grading System (GAGS) Each is derived by multiplying the factors-2 for forehead, 2 for each check, 1 for nose, 1 for chin, 3 for both chest and back by the most heavily weighted lesion within each region (1 for ≥ one comedone, 2 for ≥ one papule,3 for ≥ one pustule, and 4 for ≥ one nodule).

Secondary Outcome Measures

Liver function tests
Serum AST and ALT measure before and after 3 months therapy
Lipid profile
serum cholesterol, TG, LDL and HDL levels in blood before and after 3 months therapy
Insulin growth factor -1
Assessment of IGF-1 level in blood before and after 3 months therapy
serum amyloid A1
Assessment of serum amyloid A1 level before and after 3 months therapy
Malondialdehyde
Assessment of Malondialdehyde level in blood before and after 3 months therapy

Full Information

First Posted
December 8, 2022
Last Updated
December 18, 2022
Sponsor
Tanta University
search

1. Study Identification

Unique Protocol Identification Number
NCT05666765
Brief Title
Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris
Official Title
Comparative Study Between the Effect of Isotretinoin, Silymarin and Their Combination in the Treatment of Patients With Acne Vulgaris
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2023 (Anticipated)
Primary Completion Date
November 1, 2023 (Anticipated)
Study Completion Date
January 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tanta University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study aims to compare the effects of isotretinoin and silymarin or both in treatment of acne and their effects on the level of IGF-1, SAA1 and malondialdehyde (MDA) in acne patients.
Detailed Description
Acne vulgaris, a common and chronic disorder of the pilosebaceous unit, affects up to 85% of adolescent and young adults. The pathogenesis of acne is multifactorial. Traditionally, four distinct processes were believed to play critical roles: increased sebum production, alteration of keratinization processes leading to comedone formation, follicular colonization by Propionibacterium acnes (P.acnes) and inflammatory mediators around pilosebaceous unit. Orally administered isotretinoin is currently the only agent that can affect all four main factors implicated in acne. Serum insulin-like growth factor -1(IGF)-1 is a polypeptide hormone that has effects on sebocyte differentiation and proliferation. It leads to lipogenesis, and synthesis of inflammatory cytokines. IGF-1 also stimulates androgen synthesis leading to overproduction of sebum. Propionibacterium acnes can increase the release of serum amyloid A1 (SAA1) .There is significant elevation of SAA1 in patients with acne, with a positive correlation with its severity. Oxidative stress plays a role in the pathogenesis of acne in part due to the generation of reactive oxygen species (ROS) in response to infection by the bacterium Propionibacterium acnes, which colonizes the skin and grows in plugged hair follicles, thus attracting inflammatory cells, mainly neutrophils. These in turn secrete inflammatory mediators and generate ROS, which augments the inflammatory response and tissue damage. Silymarin, the main active component of milk thistle consists of a mixture of flavonolignans and flavonoid taxifolin. Silymarin acts as a hepatoprotective, anticancer, anti-inflammatory and immunomodulatory agent. Silymarin acts as a free radical scavenger, stabilizes the plasma membrane and reduces the production of inflammatory mediators produced by P. acnes, and scavenges the released free radicals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Prospective controlled
Masking
None (Open Label)
Allocation
Randomized
Enrollment
75 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
acne vulgaris patients group 1
Arm Type
Experimental
Arm Description
acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
Arm Title
acne vulgaris patients group 2
Arm Type
Experimental
Arm Description
acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
Arm Title
acne vulgaris patients group 3
Arm Type
Experimental
Arm Description
acne patients will be rondomly assigned to 1 of the 3 interventions (isotretinoin, silymarin, or both)
Intervention Type
Drug
Intervention Name(s)
Isotretinoin ,silymarin
Intervention Description
20mg/day isotretinoin for 3 months. 140 mg/day silymarin for 3 months. 20mg/day isotretinoin and 140mg/day silymarin for 3 months.
Primary Outcome Measure Information:
Title
Global Acne Grading Classification
Description
Global Acne Grading System (GAGS) Each is derived by multiplying the factors-2 for forehead, 2 for each check, 1 for nose, 1 for chin, 3 for both chest and back by the most heavily weighted lesion within each region (1 for ≥ one comedone, 2 for ≥ one papule,3 for ≥ one pustule, and 4 for ≥ one nodule).
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Liver function tests
Description
Serum AST and ALT measure before and after 3 months therapy
Time Frame
3 months
Title
Lipid profile
Description
serum cholesterol, TG, LDL and HDL levels in blood before and after 3 months therapy
Time Frame
3 months
Title
Insulin growth factor -1
Description
Assessment of IGF-1 level in blood before and after 3 months therapy
Time Frame
3 months
Title
serum amyloid A1
Description
Assessment of serum amyloid A1 level before and after 3 months therapy
Time Frame
3 months
Title
Malondialdehyde
Description
Assessment of Malondialdehyde level in blood before and after 3 months therapy
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: 16 years or more. Patient with moderate or severe acne. Not receiving acne treatment in the last month. Exclusion Criteria: Pregnancy or lactation. Patients with known hypersensitivity to isotretinoin or silymarin. Patients with depression, liver diseases or high cholesterol. Patients with acromegaly. Patients with chronic inflammatory, infective or neoplastic disorders.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ghada M Tantawy, Doctor
Phone
00201144062267
Email
Ghadamtantawy@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Sahar M El-hagger, Professor
Phone
0020403336007
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ghada F Hassan, A.professor
Organizational Affiliation
Tanta University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Dalia R Elafify, Doctor
Organizational Affiliation
Tanta University
Official's Role
Study Chair
Facility Information:
Facility Name
Tanta University
City
Tanta
Country
Egypt
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dalia R Elafify, Doctor
First Name & Middle Initial & Last Name & Degree
Ghada M Tantawy, Doctor

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
31393195
Citation
Hazarika N. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. J Dermatolog Treat. 2021 May;32(3):277-285. doi: 10.1080/09546634.2019.1654075. Epub 2019 Aug 29.
Results Reference
background
PubMed Identifier
31579978
Citation
Shie Morteza M, Hayati Z, Namazi N, Abdollahimajd F. Efficacy and safety of oral silymarin in comparison with oral doxycycline and their combination therapy in the treatment of acne vulgaris. Dermatol Ther. 2019 Nov;32(6):e13095. doi: 10.1111/dth.13095. Epub 2019 Oct 21.
Results Reference
background

Learn more about this trial

Comparison Between Isotretinoin, Silymarin and Both in the Treatment of Acne Vulgaris

We'll reach out to this number within 24 hrs